



**UNITED STATES DEPARTMENT OF COMMERCE**  
**Patent and Trademark Office**  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

H22

AUG 31 1992

Edward V. Filardi  
White & Case  
1155 Avenue of the Americas  
New York, NY 10036

Re: Patent Term Extension  
Application for  
U.S. Patent No. 4,264,611

### NOTICE OF FINAL DETERMINATION

A determination has been made that U.S. Patent No. 4,264,611 issued July 17, 1984, which claims the human drug product Plendil, is eligible for patent term extension under 35 USC § 156. The period of extension has been determined to be two years.

The period of extension has been calculated using the FDA determination of the length of the regulatory review period published in the Federal Register of December 19, 1991. Under 35 USC § 156 (c):

$$\begin{aligned}\text{Period of Extension} &= 1/2 \text{ (Testing Phase)} + \text{Approval Phase} \\ &= 1/2 (1,248) + 1,246 \\ &= 1,870 \text{ days}\end{aligned}$$

Since the regulatory review period began after the patent issue date, the entire period has been considered. No determination of a lack of due diligence was made.

The two year limitation of 35 USC § 156 (g) (6) (C) applies in the present situation because: (1) the patent was issued before the date of enactment (September 24, 1984) of 35 USC § 156; (2) the date an exemption under subsection 505 (i) of the Federal Food, Drug and Cosmetic Act involving the approved product was submitted (August 24, 1984) was before the date of enactment; and, (3) the date the new drug application was approved (July 25, 1991) was after the date of enactment. Since the period of extension calculated under 35 USC § 156 (c) for the patent cannot exceed two years under 35 USC § 156 (g) (6) (C), the period of extension will be for two years.

The 14 year exception of 35 USC § 156 (c) (3) does not operate to further reduce the period determined above.

A single request for reconsideration of this final determination as to eligibility and the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136 (a) are not applicable to this time period. In the absence of such request for reconsideration, the Commissioner will issue to the applicant for extension of the term of Patent No. 4,264,611 a certificate of extension, under seal, for a period of two years.

Upon issuance of the certificate of extension the following information will be published in the Official Gazette:

U.S. Patent No.:	4,264,611
Granted:	July 17, 1984
Applicant:	Pedar B. Berntsson et al
Owner of Record:	Aktiebolaget Astra
Title:	2, 6 - DIMETHYL - 4 - 2, 3 - DISUBSTITUTED PHENYL - 1, 4 - DIHYDRO- PYRIDINE - 3, 5 - DICARBOXYLIC ACID - 3, 5 - ASYMMETRIC DIESTERS HAVING HYPOTENSIVE PROPERTIES, AS WELL AS METHOD FOR TREATING HYPERTENSIVE CONDITIONS AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
Classification:	514/356
Product Trade Name:	Plendil
Term Extended:	Two years

*C. E. Van Horn*

Charles E. Van Horn  
Patent Policy & Projects Administrator  
Office of the Assistant Commissioner for Patents

cc: Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs (HFY-20)  
Food and Drug Administration  
5600 Fishers Lane, Room 11-44  
Rockville, MD 20857

RE: Plendil  
FDA Docket No.: 91E - 0377